In CD19 CAR T cells, the 40x lower recognition domain CAR induced significantly less toxicities including CRS and ICANS compared to FMC63-based CAR T cells in childhood BCP-ALL patients while demonstrating enhanced proliferative capacity and antitumor activity (108). Here, CD19 is linked to acute lymphoblastic leukemia.